Starling Oncology, Inc. (STLN)
Starling Oncology, Inc. (STLN) from its SEC filings: 2025 revenue $502.7 million (+28% vs the year before), net margin 12055%, free cash flow -$27.8 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Services-Offices & Clinics Of Doctors Of Medicine |
| Revenue (2025) | $502.7 million |
| Revenue growth | +28% |
| Net income | $60.6 billion |
| Net margin | 12055.4% |
| Free cash flow | -$27.8 million |
| Diluted EPS | $-0.54 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +35% |
| Cash | $200,000 |
| Long-term debt | $79.9 million |
| Share count, 1 year | +9% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.